Team
Jon Amund Eriksen, MSc
Chief Executive Officer
Mr. Eriksen, a founder of Hubro Bioscience, has extensive industrial R&D experience from leadership positions at several biotech and pharmaceutical companies. With more than 40 years R&D experience and 35 years within the field of cancer immunotherapy and is an inventor and co-inventor of several patents and patent applications. He has experience from establishing business collaboration and licensing deals, M&A and IPO. Co-founder of Gemvax AS, Targovax ASA and Hubro Therapeutics AS. Mr. Eriksen is educated as a chemist (MSc) from the University of Oslo, Norway.
Sarah J. Arbe-Barnes, PhD
Chief Operating Officer
Dr Sarah Arbe-Barnes, a founder of Hubro Bioscience, with over 30 years of biotech and consulting experience in a range of leadership roles and therapeutic areas, with a PhD in Biochemistry from the University of Bath, UK, has led multiple global product development programmes. A founder of both Fulcrum and Artemida.
Robert M. Miller, MD
Chief Medical Officer
Dr Robert Miller, a founder of Hubro Bioscience, with well over 30 years of R&D experience particularly in oncology including cancer immunotherapy, is a Physician with a license to practice with degrees from the University of London, the Royal College of Surgeons and is a Fellow of the Faculty of Pharmaceutical Medicine. A founder of both Fulcrum and Artemida.
Henrik K. Eriksen, MSc
Chief Technology Officer
Mr. Kvalheim Eriksen, a founder of Hubro Bioscience, has 5 years of R&D experience within the field of immunotherapy of cancer from Hubro Therapeutics AS before the foundation of Hubro Bioscience AS. He is the inventor of the company’s proprietary frameshift detection technology. With his molecular biology and microbiology background, he has been responsible for and led the technical development of the company’s technology platform. Mr. Kvalheim Eriksen holds a MSc in molecular biology from the University of Oslo, Norway.
Board of Directors
Jon Amund Eriksen, MSc
Chairman of the Board of Directors
Mr. Eriksen, a founder of Hubro Bioscience, has extensive industrial R&D experience from leadership positions at several biotech and pharmaceutical companies. With more than 40 years R&D experience and 35 years within the field of cancer immunotherapy and is an inventor and co-inventor of several patents and patent applications. He has experience from establishing business collaboration and licensing deals, M&A and IPO. Co-founder of Gemvax AS, Targovax ASA and Hubro Therapeutics AS. Mr. Eriksen is educated as a chemist (MSc) from the University of Oslo, Norway.
Tom A. Thorsen
Deputy Chairman of the Board of Directors
Mr. Thorsen is the CEO at Algot Invest AS. Following two and a half decades of executive management, board level roles and investments, Mr. Thorsen is a seasoned investor with extensive experience in commercialization, M&A processes and acting as a dealmaker, board member and owner in several successful companies.
Mr. Thorsen was previously a board member in Tantan, which was successfully sold to Momo (NASDAQ, China’s leading mobile networking platform) in February 2018. He has also held positions as board member in Targovax and OncoImmunity, the latter which was successfully sold in 2019 to Japanese NEC.
Robert M. Miller, MD
Board Member
Dr Robert Miller, a founder of Hubro Bioscience, with well over 30 years of R&D experience particularly in oncology including cancer immunotherapy, is a Physician with a license to practice with degrees from the University of London, the Royal College of Surgeons and is a Fellow of the Faculty of Pharmaceutical Medicine. Founder of Fulcrum and Artemida.